The generic alternative in schizophrenia: Opportunity or threat?

CNS Drugs

Volumn 18, Issue 12, 2004, Pages 769-775

  Nuss, Philippe ^a   Taylor, David ^b   De Hert, Marc ^c   Hummer, Martina ^d  

^a HÔPITAL SAINT ANTOINE   (France)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; GENERIC DRUG;

AREA UNDER THE CURVE; BIOEQUIVALENCE; DRUG ABSORPTION; DRUG COST; DRUG FORMULATION; DRUG HALF LIFE; HEALTH CARE COST; HEALTH CARE POLICY; HOSTILITY; HUMAN; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RELAPSE; REVIEW; SCHIZOPHRENIA; SOCIAL SUPPORT; SYMPTOMATOLOGY;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; DRUGS, GENERIC; HUMANS; PATIENT ACCEPTANCE OF HEALTH CARE; PUBLIC HEALTH; SCHIZOPHRENIA; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME;

EID: 7044241169     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200418120-00002     Document Type: Review

References (31)

1. Jablensky A. Epidemiology of schizophrenia: the global burden of disease and disability. Eur Arch Psychiatry Clin Neurosci 2000; 250: 274-85
2. Meredith PA. Generic drugs: therapeutic equivalence. Drug Saf 1996; 15: 233-42
3. Colaizzi JL, Lowenthal DT. Critical therapeutic categories: a contraindication to generic substitution? Clin Ther 1986; 8: 370-9
4. Ess SM, Schneeweiss S, Szucs TD. European healthcare policies for controlling drug expenditure. Pharmacoeconomics 2003; 21 (2): 89-103
5. Kanavos P, Reinhardt U. Reference pricing for drugs: is it compatible with US health care? Health Aff (Millwood) 2003 May-Jun; 22 (3): 16-30
6. European Agency for the Evaluation of Medicinal Products. Note for guidance on the investigation of bioavailability and bioequivalence. London: EMEA, 2001 Jul 26 (CPMP/EWP/QWP/1401/98)
7. Meredith P. Bioequivalence and other unresolved issues in generic drug substitution. Clin Ther 2003; 25: 2875-90
8. Borgherini G. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. Clin Ther 2003; 25: 1578-92
9. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: average, population, and individual approaches to establishing bioequivalence, draft guidance August 1999 [online]. Available from URL: http://www.fda.gov/cder/ guidance/1716dft.htm [Accessed 2004 Jul 5]
10. World Health Organization. Multi-source pharmaceutical products: WHO guideline on registration requirements to establish interchangeability. Geneva: WHO, 1996. WHO Technical Support Series no. 863
11. Chen ML, Patnaik R, Hauck WW, et al. An individual bioequivalence criterion: regulatory considerations. Stat Med 2000; 19: 2821-42
12. Cutler NR. Pharmacokinetic studies of antipsychotics in healthy volunteers versus patients. J Clin Psychiatry 2001; 62 Suppl. 5: 10-3
13. Burns T, Chabannes JP, Demyttenaere K. Switching antipsychotic medications: general recommendations and switching amisulpride. Curr Med Res Opin 2002 18 (4): 201-8
14. Lindstrom E, Bingefors K. Patient compliance with drug therapy in shizophrenia: economic and clinical issues. Pharmacoeconomics 2000; 18: 106-24
15. Hellewell JS. Patients' subjective experiences of antipsychotics: clinical relevance. CNS Drugs 2002; 16: 457-71
16. Robinson DG, Woerner MG, Alvir JM, et al. Predictors of medication discontinuation by patients with first episode schizophrenia and schizoaffective disorder. Schizophr Res 2002; 57: 209-19
17. Genduso LA, Haley JC. Cost of illness studies for schizophrenia: components, benefits, results and implications. Am J Manag Care 1997; 3: 873-7
18. Thieda P, Beard S, Richter A, et al. An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr Serv 2003; 54: 508-16
19. Banahan III BF, Kolassa EM. A physician survey on generic drugs and substitution of critical dose medications. Arch Intern Med 1997; 18: 157: 2080-8
20. Iijima H, Kurosaki T, Kamei M, et al. Calculation of drug information necessity factor of generic drugs [in Japanese]. Yakugaku Zasshi 2003; 123: 1039-47
21. Generali JA, Hogan L. A comparison of pharmaceutical manufacturers as a source of drug information to a telephone inquiry: generic vs brand. Drug Inf J 1983; 17: 195-200
22. Thomas M, Lexchin J. Responsiveness to physicians' requests for information concerning drug interactions: a comparison of brand and generic companies. Soc Sci Med 1990; 31: 153-7
23. Tilyard MW, Dovey SM, Rosenstreich D. General practitioners' views on generic medication and substitution. N Z Med J 1990; 103: 318-20
24. Brust M, Hawkins CF, Grayson D. Physicians' attitudes toward generic drug substitution by pharmacists. Tex Med 1990; 86: 45-9
25. Carroll NV, Wolfgang AP. Inherent risk and market acceptance of generic drug products. J Health Care Mark 1989; 9: 48-51
26. Vasquez EM, Min DI. Transplant pharmacists' opinions on generic product selection of critical-dose drugs. Am J Health Syst Pharm 1999; 56: 615-21
27. Pelton LE, Strutton D, Smith MC. A political economy perspective: why pharmacists may be reluctant to dispense generic medications. J Hosp Mark 1994; 9: 137
28. Lam YW, Ereshefsky L, Toney GB, et al. Branded versus generic clozapine: bioavailability comparison and interchangeability issues. J Clin Psychiatry 2001; 62 Suppl. 5: 18-22
29. Kluznik JC, Walbek NH, Farnsworth MG, et al. Clinical effects of a randomized switch of patients from clozaril to generic clozapine. J Clin Psychiatry 2001; 62 Suppl. 5: 14-7
30. Makela EH, Cutlip WD, Stevenson JM, et al. Branded versus generic clozapine for treatment of schizophrenia. Ann Pharmacother 2003; 37: 350-3
31. Verster GC, Joubert G, Stevens M, et al. Generic substitution: comparing the clinical efficacy of a generic substitute for fluphenazine decanoate with the original product. S Afr Med J 1998; 88: 260-2